Cloximate is a non-steroidal anti-inflammatory drug, developed in the Dutch company Philips-Duphar B.V. Research Laboratories in the 1970s. Cloximate acts by inhibition of PGE2 biosynthesis. In preclinical experiments, cloximate showed good inhibitory activities in local exudative tests, in the proliferative and functional aspects of experimental inflammation, as well as in the bradykinin-evoked bronchoconstriction test. Cloximate showed almost no harmful effects on the gastrointestinal mucosa and no influence upon the emptying rate of the stomach. Cloximate was evaluated in double-blind clinical trials, where different formulations were compared with naproxen. Gastrointestinal blood loss increased more in the naproxen group than in the group treated with non-enteric coated cloximate.

Nortopixantrone (BBR-3438), a member of the 9-aza-anthrapyrazole family, is a DNA topoisomerase inhibitor potentially designed for the treatment of gastric cancer, ovarian cancer. BR 3438 exhibited a unique profile of preclinical activity with a superior efficacy against prostatic carcinoma models compared to reference compounds (doxorubicin and losoxantrone). Nortopixantrone had been in phase II clinical trials with Novuspharma for the treatment of gastric cancer, ovarian cancer and prostate cancer. But this research was discontinued in 2002.

Metrenperone, a 5-hydroxytryptamine blocker, is used in veterinary as an antimyopathic agent. Experiments on rabbits have shown that the drug had positive effects on collagen turnover, remodeling, and organization during acute inflammation and fibroplasia.

Iodecimol is nonionic-dimeric contrast medium patented by Schering A.-G. for myocardial imaging

Opaviraline (also known as GW 420867), a nonnucleoside reverse transcriptase inhibitor that was studied for the treatment of HIV infections. The drug participated in clinical trials phase II in Germany, in South Africa, and in the United Kingdom, however, these studies were discontinued.

Olradipine (also known as S 11568) is a L-type Ca(2+) channel antagonist. This drug was being developed in France for the treatment of heart failure, hypertension, and ischemic heart disorder. However, all these studies were discontinued.

Febuverine is a spasmolytic and local anesthetic.

Tuvatidine (HUK 978) is a potent H2-antagonist. HUK 978 was shown to be devoid of activity at the histamine H1-receptor, the muscarinic receptor and the alpha and beta-adrenergic receptors. In both the guinea-pig gastric mucosa preparation and the rat perfused stomach model, HUK 978 was a powerful inhibitor of acid secretion. HUK 978 is a highly specific H2-antagonist and inhibits acid secretion for longer periods than other competitive compounds.

FLUBANILATE is a CNS stimulant.

FLUDOXOPONE is an anticholesterolemic agent.